Kisspeptin and PT-141 get compared because they end up in the same sentence — peptides studied for sexual desire. Biologically they could hardly be less alike: one sits at the top of the reproductive hormone axis, the other fires melanocortin receptors in the brain's arousal circuitry.
PT-141 (bremelanotide) is the one with an FDA approval — for hypoactive sexual desire disorder in premenopausal women — and with published re-analyses questioning how large its benefit really is. Kisspeptin has small, controlled academic studies showing modulation of sexual brain processing, including penile tumescence effects in men — promising, earlier-stage, and not a product.
What each molecule actually is
Kisspeptin is an endogenous neuropeptide encoded by KISS1, best known as the master upstream regulator of gonadotropin release — the switch above GnRH in the reproductive axis. Its sexual-behavior research rides on the observation that kisspeptin neurons also project into limbic circuits that process attraction and arousal.
PT-141 (bremelanotide) is a synthetic melanocortin agonist — a metabolite of melanotan II — acting mainly at MC4 receptors in central arousal pathways. It reached the market as Vyleesi, an on-demand subcutaneous injection approved for premenopausal hypoactive sexual desire disorder (HSDD).
The kisspeptin evidence: small, controlled, mechanistic
The strongest kisspeptin work is a set of double-blind, placebo-controlled crossover studies from a single London group. In men with low sexual desire, kisspeptin infusion modulated sexual and attraction brain processing on fMRI and — the finding that traveled — increased penile tumescence in response to erotic stimuli. Participant numbers sit in the dozens, the exposure is an intravenous infusion in a lab, and the endpoints are mechanistic rather than clinical.
That is a real signal and an early one. No kisspeptin product exists for this use, no at-home formulation has been trialed, and duration-of-effect questions are open.
The PT-141 evidence: approved, and argued about
Bremelanotide's approval rests on the RECONNECT phase-3 program in premenopausal women with HSDD: statistically significant improvements in desire scores and distress versus placebo, consistent across prespecified subgroups, with a safety profile dominated by nausea (about 40%), flushing and headache, plus transient blood-pressure rises that shaped the labeling.
The counterweight: independent re-analyses of the trial data argue the average benefit is small — fractions of a point on the desire scale — and note high discontinuation. An approved drug with a debated effect size is still a fundamentally different evidentiary position from an academic infusion study; it is just a less triumphant one than the marketing suggests.
PT-141
The melanocortin peptide discussed here, supplied as research-use-only material with a batch-matched certificate of analysis.
Head to head, honestly
| Kisspeptin | PT-141 (bremelanotide) | |
|---|---|---|
| Receptor target | KISS1R; upstream of GnRH | Melanocortin receptors (MC4-centric) |
| Best human evidence | Placebo-controlled crossover fMRI/tumescence studies, dozens of subjects | Phase-3 RCTs in ~1,200 women; FDA approval (Vyleesi) |
| Population studied | Men and women with low desire, lab setting | Premenopausal women with HSDD |
| Effect size debate | Too early to quantify clinically | Published re-analyses argue benefit is small |
| Tolerability signal | Well tolerated in short infusions | Nausea ~40%, flushing, transient BP rise |
| Status | Research hormone, no product | Approved drug; also sold as research material |
Why the comparison usually asks the wrong question
"Which is better" assumes the two are competing answers to one question. They are not: kisspeptin research asks whether the reproductive axis's master switch also gates desire circuits; bremelanotide is a receptor-level arousal drug with a marketing history. A researcher interested in axis biology reads the kisspeptin literature; a question about the only approved desire peptide is a bremelanotide question — including the re-analysis literature, which is as instructive as the trials.
PT-141
Research-use-only material, sold by the vial with batch documentation. Check the certificate of analysis against the batch you receive.
What to know now
- Different biology entirely: kisspeptin sits atop the reproductive hormone axis; PT-141 fires central melanocortin receptors.
- PT-141 is the one with an FDA approval (Vyleesi, premenopausal HSDD) — and with published re-analyses arguing the average benefit is small.
- Kisspeptin's controlled studies show modulated sexual brain processing and increased penile tumescence — mechanistic findings in dozens of subjects, not clinical endpoints.
- Tolerability profiles differ: short kisspeptin infusions read clean; bremelanotide's trials logged ~40% nausea and transient blood-pressure rises.
- The two literatures barely overlap — treat "which is better" as two separate research questions wearing one comparison.
What we're watching
Whether kisspeptin work moves from infusion studies toward a practical formulation and clinical endpoints — and whether any post-marketing bremelanotide data shifts the effect-size argument either way.
Frequently asked questions
Is kisspeptin better than PT-141?
They are not interchangeable. PT-141 (bremelanotide) has phase-3 trials and an FDA approval for premenopausal HSDD, with re-analyses debating how large the benefit is. Kisspeptin has smaller, earlier, placebo-controlled mechanistic studies — a promising signal, not a clinical track record.
Does kisspeptin increase testosterone?
Kisspeptin stimulates the GnRH–LH axis, and infusion studies report downstream hormonal responses. Its sexual-processing findings, however, appear to involve brain circuits directly rather than being explained by acute testosterone changes.
What are PT-141's most common side effects?
Across the clinical program: nausea (the dominant one, around 40%), flushing, headache, and transient increases in blood pressure — the reason for the drug's usage cautions in labeling.
Is PT-141 the same as melanotan II?
PT-141 is an active metabolite of melanotan II, developed after tumescence was observed in melanotan studies. Melanotan II itself remains an unapproved tanning peptide with a separate — and messier — safety literature.
References
- Mills, E. G., Yang, L., Abbara, A., et al. (2023). Effects of kisspeptin on sexual brain processing and penile tumescence in men with hypoactive sexual desire disorder. JAMA Network Open, 6(2), e2254313. https://doi.org/10.1001/jamanetworkopen.2022.54313
- Pfaus, J. G., Sadiq, A., Spana, C., & Clayton, A. H. (2022). The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women. CNS Spectrums, 27(3), 281–289. https://doi.org/10.1017/S109285292100002X
- Simon, J. A., Kingsberg, S. A., Portman, D., et al. (2022). Prespecified and integrated subgroup analyses from the RECONNECT phase 3 studies of bremelanotide. Journal of Women's Health, 31(3), 391–400. https://doi.org/10.1089/jwh.2021.0225
- Clayton, A. H., Kingsberg, S. A., Portman, D., et al. (2022). Safety profile of bremelanotide across the clinical development program. Journal of Women's Health, 31(2), 171–182. https://doi.org/10.1089/jwh.2021.0191
- Spielmans, G. I. (2021). Re-analyzing phase III bremelanotide trials for "hypoactive sexual desire disorder" in women. Journal of Sex Research, 58(9), 1085–1105. https://doi.org/10.1080/00224499.2021.1885601
- Spielmans, G. I., & Ellefson, E. M. (2024). Small effects, questionable outcomes: Bremelanotide for hypoactive sexual desire disorder. Journal of Sex Research, 61(4), 540–561. https://doi.org/10.1080/00224499.2023.2175192
- Mestria, S., Odoardi, S., Frison, G., & Strano Rossi, S. (2021). LC-HRMS characterization of melanotan II and bremelanotide sold on the black market. Drug Testing and Analysis, 13(4), 876–882. https://doi.org/10.1002/dta.2986